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igM antibodies against phosphorylcholine (anti-pc) and malondialdehyde (anti-MDA) may have 
protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in 
systemic rheumatic conditions and study their properties. Anti-pc and anti-MDA was measured using 
ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic 
sclerosis (SSc, 331), Sjögren’s syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), 
undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). 
Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and 
anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing 
approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was 
determined by flow cytometry. The maximal difference between cases and controls was shown for 
MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 
in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc 
and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-
MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient 
group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, 
Anti-pc is decreased in MctD and also in SLe, SjS and SSc but not in other studied diseases. Anti-pc 
may thus differentiate between these. In contrast, anti-MDA did not show these differences between 
diseases studied. Anti-pc level is negatively correlated with cV in the patient group cohort. in contrast 
to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic 
and therapeutic implications, one possibility being active or passive immunization with pc in some 
rheumatic conditions.
Systemic autoimmune diseases (SADs) is present among up to 3–5% of population in westernized societies. Their 
pathogenesis involves varying degree of chronic inflammation but usually the underlying causes remain elusive. 
A common feature is autoimmune reactions and specific autoantibodies and current diagnosis is typically based 
on a combination of autoantibody patterns and clinically related criteria1–3.
In the present study, PRECISESADS (Precision medicine strategies for Systemic Autoimmune Diseases) 
patients with various autoimmune diseases: SLE (Systemic Lupus Erythematosus), RA (Rheumatoid Arthritis), 
SjS (Sjögren´s syndrome), SSc (Systemic Sclerosis), MCTD (Mixed Connective Tissue Disease), PAPs (Primary 
Antiphospholipid syndrome) and UCTD (Undifferentiated Connective Tissue Disease), were recruited.
The SADs patients present multiple co-morbidities, and an important one is cardiovascular diseases, often 
based on increased atherosclerosis4–7. Phosphorylcholine (PC) is a damage associated molecular pattern 
(DAMP)8 and also a pathogen associated molecular pattern (PAMP)9,10 while malondialdehyde (MDA) is mainly 
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considered a DAMP11. Both form adducts with proteins and are recognized by the immune system. As a conse-
quence, anti-PC and anti-MDA IgM antibodies are present at relatively high concentrations in healthy adults. 
Since recognized antigens are normally present in humans these IgMs could be considered autoantibodies12–15.
We have reported protective associations for IgM anti-PC in different chronic inflammatory disease condi-
tions. It is negatively associated with cardiovascular disease including stroke and myocardial infarction (MI), 
atherosclerosis increase after four years, and also mortality after MI12–14. IgM anti-PC could also play a role in SLE 
being associated with the disease itself, and also with atherosclerotic plaques and vulnerable plaques in SLE16,17. 
Further, low anti-PC is associated with being a non-responder to biologics in RA18. These and similar findings 
have largely been confirmed and extended into other diseases like vasculitis and even osteoarthritis19–25.
Less is known about clinical role of anti-MDA IgM. We reported that in SLE, anti-MDA is a protection marker, 
especially together with anti-PC26 and anti-MDA is also a protection marker for development of CVD among 
60-year olds15.
We here determine anti-PC and anti-MDA in the patients studied and compared with healthy controls. We 
also compare anti-PC and anti-MDA with peptide/protein characterization using a proteomics de novo sequenc-
ing approach and study effects of these antibodies on T regulatory cells (Tregs).
Materials and Methods
In the PRECISESADS study, patients with SLE (n = 374), RA (n = 354), MCTD (n = 77), SSc (n = 331), SjS 
(n = 324), PAPs (n = 65), UCTD (n = 118) and 515 age- and sex-matched healthy controls (HC) were investi-
gated. This study and classification of patients has been described previously27. The participants were recruited, 
and samples were obtained in accordance with the Declaration of Helsinki. All participants gave informed written 
consent to participating in the study. Ethical approval was granted at each participating site by the ethics commit-
tee/institutional review board at the following institutions:
 Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico di Milano, Italy;
Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France;
 Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et 
Clinique, Université catholique de Louvain, Brussels, Belgium;
Centro Hospitalar do Porto, Portugal;
Servicio Cantabro de Salud, Hospital Universitario Marqués de Valdecilla, Santander, Spain;
Hospital Clinic I Provicia, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;
Katholieke Universiteit Leuven, Belgium;
Klinikum der Universitaet zu Koeln, Cologne, Germany;
Medizinische Hochschule Hannover, Germany;
Medical University Vienna, Vienna, Austria;
Servicio Andaluz de Salud, Hospital Universitario Reina Sofía Córdoba, Spain;
 Servicio Andaluz de Salud, Complejo hospitalario Universitario de Granada (Hospital Universitario San 
Cecilio), Spain;
 Servicio Andaluz de Salud, Complejo hospitalario Universitario de Granada (Hospital Virgen de las Nieves), 
Spain;
Servicio Andaluz de Salud, Hospital Regional Universitario de Málaga, Spain;
Università degli studi di Milano, Milan, Italy;
Hospitaux Universitaires de Genève, Switzerland;
University of Szeged, Szeged, Hungary;
Charite, Berlin, Germany;
Andalusian Public Health System Biobank, Granada, Spain
cardiovascular score (cV) estimation. We estimated the cardiovascular (CV) score based on the 
presence of cardiovascular-related symptoms including: Arrythmia, Coronary artery disease, Hypertension, 
Pericarditis, Pulmonary arterial hypertension by right-heart catheterization, Pulmonary hypertension on Echo, 
Valve lesions, Arterial/Venous thrombosis, Gangrene of the fingers, History of Raynaud’s phenomenon, History 
of recurrent miscarriage or pregnancy complications and Ischemic digital ulcers/Pitting scars. For the current 
study, we didn’t discriminate between particular cardiovascular symptoms and comorbidities, but estimated the 
combined score (CV score). According to clinical data, the particular CV feature could be known for the patient 
in the past or present at the moment of blood sampling. We assigned the following values for each patient: “2”, 
if CV symptom or comorbidity is present, “1”, if it was described for this patient in the past, “0” for absence or 
unknown status. For each patient CV score these values were summarized. CV score among studied individuals 
varied from 0 to 16.
igM measurement by eLiSA. Levels of IgM antibodies against PC14,17 or MDA15,26 were determined by 
enzyme-linked immunosorbent assay (ELISA), as described in detail previously14,15,17,26. PC was conjugated with 
bovine serum albumin (BSA) and MDA was conjugated with human serum albumin (HSA; (Sigma-Aldrich AB, 
Stockholm, Sweden)). NUNC immune plates were coated with PC-BSA or MDA-HSA at 10 μg/mL, overnight. 
Plates were washed with PBS containing 0.5% tween (PBST) four times and blocked with 2% BSA for 90 min at 
room temperature (RT). Plates were washed again. Standards and serum were added at 100 μl/well in duplicates 
at 1:100 dilution, which was further incubated for two hours at RT. Further, secondary antibodies at (1:3500) for 
PC-BSA and (1:1500) for MDA-HSA were added and incubated at RT for two hours. The color was developed 
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with pNPP substrate by incubating for 75 min at RT. Finally, the reaction was stopped with 3 M NaOH and the 
plates were read with spectrophotometer at 405 nm. The Relative Unit (RU) were measured by the formula given 
below,
= − ∗
−
(Absorbance of sample) (Absorbance of blank) 100
(Absorbance of Standard) (Absorbance of blank)
Studies of T-regulatory cells. Generation of Tregs were performed as described previously28. Briefly, 
peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors, according to the manufac-
turer’s protocol (Ficoll-Paque PLUS, GE Healthcare, Buckinghamshire, United Kingdom). The cells were added 
to a tissue culture plate pre-coated with anti-CD3 antibody (10 μg/mL) (eBioscience, CA, USA), together with 
soluble anti-CD28 antibody (1 μg/mL) (eBioscience, CA, USA), IL-2 (10 ng/mL), TGF-β1 (10 ng/mL) (Immuno 
Tools, Friesoythe, Germany), in culture medium for six days and Tregs were stimulated with phorbol myristate 
acetate (50 ng/mL) and Ionomycin (1 μg/mL) (Sigma-Aldrich, St Louis, USA) 5 h on the harvest day. Anti-PC and 
anti-MDA IgM (5 μmol/L) and their respective flow through (FT) were added one day before harvest. PBMCs 
were resuspended in FACS buffer. For Treg staining, cells were incubated with human Treg cocktail (CD4/CD25/
CD127) (BD Bioscience, CA, USA). Experiments were performed with the BD LSRFortessa™ cell analyzer (BD 
Bioscience, CA, USA) and analysed using flowJo.
Preparation of IgM anti-PC and anti-MDA. Anti-PC and anti-MDA were extracted as previously 
described15,26. Briefly, PC-BSA and MDA-HAS, 1 mg/mL was coupled to Hitrap NHS column (GE Healthcare, 
Sweden). Human IgM (Sigma Aldrich, Israel) was passed through Sepharose column coupled with PC-BSA 
and MDA–HSA. Unbound IgM considered as non-anti-MDA or non-anti-PC (mentioned as flow through, FT) 
was collected by washing the columns with binding buffer followed by elution with 0.1 mol/L glycine–HCl, elu-
tion buffer. The eluted antibodies were desalted in PD-10 columns (GE Healthcare, UK) and concentrated by a 
Centriprep centrifugal filter (Millipore, Ireland). After filtration through a 0.22-lm filter (Sarstedt, Germany), 
extracted antibodies were stored at −20 °C.
igM protein and peptide characterization. Sample preparation, LC-MS/MS analysis and data process-
ing of the anti-MDA and the anti-PC IgM samples have been described elsewhere15,28. Data processing was per-
formed using Spotlight proteomics approach29.
Note, that all samples were prepared and analyzed at the same occasion, thus the differences between anti-PC 
and anti-MDA are more likely due to true biological differences and not to differences according to variation in 
sample preparation and instrumentation. Briefly, triplicates of the samples: anti-MDA versus flow through [FT] 
deprived from anti-MDA as well as quadruplicates of the samples: anti-PC versus FT deprived from anti-PC 
were prepared. Samples were reduced (20 mM dithiothreitol, 30 min, 56 °C), alkylated (66 mM iodoacetamide 
for 30 min, in the dark) and digested with trypsin (at a ratio of 1:30 enzyme:protein, 37 °C overnight). Peptides 
were desalted using C18 StageTips (Thermo Scientific), dried in a SpeedVac and resuspended in 0.1% formic acid 
and 1% acetonitrile. Samples were injected onto a reversed phase 15 cm column (PepMap, C18, 3μm, 100 Å) in 
1 µg aliquots using a nano-liquid chromatography system Ultimate 3000 connected to a Fusion Orbitrap mass 
spectrometer (both - ThermoFisher Scientific). Briefly, survey mass spectra were acquired in the range of m/z 
300–1700 with a nominal resolution of 120,000. Precursor ion HCD and ETD fragmentation was performed. Raw 
data processing was performed using the Spotlight proteomics approach which combines quantitative proteomics 
analysis of de novo sequenced peptides and known peptide sequencing. The abundances of IgM peptides were 
normalized so that the total abundance was the same (100%) in all samples.
Differences between anti-PC, anti-MDA and non-specific IgM peptides were tested using 2-tailed Student 
t-test with equal or unequal variance depending upon F-test. Principal component analysis (PCA) and 
Orthogonal Projections to Latent Structures Discriminate Analysis (OPLS-DA) were performed using SIMCA 
14.0 (Umetrics, Umeå, Sweden) following mean centering, log scaling, and univariate scaling.
Statistical analysis. The antibody levels were used for cases vs controls and cross-disease analysis. Statistical 
differences were estimated using parametric tests, using 2-tailed t-test with equal or unequal variance depend-
ing upon F-test. We applied Shapiro Wilk and Jarque–Bera tests to check the data for normality. The additional 
non-parametric Epps-Singleton test was carried out for distributions comparison. Percentiles were estimated 
using total dataset for all cases and healthy controls for each antibody. The correlation between antibody level and 
cardiovascular score (CV) was estimated using Spearman’s rank test.
For analysis of the level changes of both anti-PC and anti-MDA for MCTD the samples were characterized 
according to IgM level percentiles and the fraction of samples was estimated for heatmap construction.
Results of experiments with Treg polarization are expressed as mean ± standard error of mean. Effects of 
IgM anti-PC, anti-MDA or control antibodies were compared by two-tailed paired t-test. For all statistical tests a 
p < 0.05 was considered significant. Correlation between different runs of antibodies was calculated by Spearman 
correlation.
ethics approval and consent to participate. The study was performed in accordance with the 
Declaration of Helsinki and was approved by ethical committees at each site for the respective sub-cohorts. All 
subjects gave informed written consent before entering the study.
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Results
Characteristics of PRECISESADS patients. The characteristics of PRECISESADS patients are presented 
in Table 1. Although the diseases have different clinical manifestations, they are highly prevalent in females 
(70.2%-92,4%). The patients have higher CV scores compared to the controls. IgMs against PC and MDA were 
measured for all the patients and control, and their Relative units, were presented as seen in Table 1. Since these 
diseases were female biased, we analyzed female-only subset. Intra-assay variability was <10%. When 288 sam-
ples were run two times separately, the correlation, R, was 0.988 for IgM anti PC and 0.978 for IgM anti-MDA.
Anti-pc and anti-MDA levels among cases and controls. Different systemic rheumatic diseases 
demonstrated variant distribution of anti-PC and anti-MDA levels (Fig. 1A–E). IgM levels were distributed nor-
mally in the total dataset as well as in the healthy controls and all diseases combined subsets (Shapiro Wilk 
p(normal) for anti-PC/anti-MDA = 2.16E-20/5.63E-29, 1.34E-25/8.57E-30 and 1.33E-12/4.54E-07, respectively, 
Jarque-Bera p(Monte-Carlo) = 0.0003 for disease-only anti-PC and 0.0001 for other datasets). The most prom-
inent changes in mean values in comparison with both healthy controls and other diseases were detected for 
MCTD with more pronounced level decrease for anti-PC (p = 0.008) than for anti-MDA (p = 0.122). Additional 
non-parametric Kruskal-Wallis test for the MCTD subset (65 samples) also supported importance of anti-PC 
IgM for this disease (Dunn posthoc corrected p (same) = 0.005559, in contrast to 0.1777 for anti-MDA). In the 
cross-sectional data, mostly the anti-PC mean level was significantly different between disorders or HC-disorders 
in pairwise comparison. Low levels of IgMs were the most prevalent in MCTD, both anti-PC and anti-MDA. 
Also IgM low levels were more frequent in SjS, SLE, SSc and UCTD, more for anti-PC than for anti-MDA (Suppl. 
Fig. 1). Variance based tests shown more significant differences in anti-PC IgM than for anti-MDA for most 
of diseases, including MCTD, SjS, RA and SLE (Fig. 1). Low levels of both anti-PC and anti-MDA in the same 
samples were prevalent in MCTD and SLE but not in HC and were also detected in other disease cohorts, SLE in 
particular (Fig. 1E).
cardiovascular co-morbidities. The frequent cardiovascular comorbidities were described for patients 
as shown in Fig. 2. We estimated the cardiovascular (CV) score based on the presence of cardiovascular-related 
symptoms and that it correlates with IgM anti-PC and anti-MDA. We demonstrate that for the combined patient 
cohort anti-PC IgM is significantly negatively correlated with the CV score, but not anti-MDA (Spearman’s rank 
correlation p-value 8.3E-05, 8.6-E07 and 0.64). Anti-MDA level correlated with CV score only for MCTD and 
RA, but not with other diseases. In contrast, for anti-PC IgM this correlation was significant for MCTD, RA, SLE 
and UCTD but not the healthy controls. Presented data are for females only. Males were few in diseases studied, 
but when included, data were similar as for women (data shown).
Effects of IgM anti-PC and anti-MDA IgM on the induced-Treg proportion in PBMCs of Healthy 
donors. To investigate if IgM anti-MDA promotes polarization of Tregs in a similar way as we have previously 
reported for anti-PC, we cultured PBMC from three healthy blood donors, and treated them in parallel either 
with anti-PC, anti-MDA and Ft (for the respective antibody). While IgM anti-PC increased Tregs upon anti-PC 
IgM addition as reported previously (the three experiments were included in the pooled results presented before), 
but anti-MDA did not promote any significant differences in Treg proportions (Fig. 3).
Proteomic comparative analysis of polyclonal anti-PC and anti-MDA variable regions. We have 
previously published quantitative LC-MS/MS peptide sequencing data from the anti-PC variable region28 and the 
anti-MDA variable region15.
Herein we reanalyzed the data to compare and identify potential similarities and differences between the 
two antigens specific IgM peptide profiles with focus on peptides derived from the variable region (i.e. peptides 
Samples Males Females Male,%
Cardiovascular 
comorbidities 
score, average 
(min – max)
Average 
age, all
Average 
age, 
males
Average 
age, 
females
Anti-PC 
IgM units 
(mean ± SD)
Anti-MDA 
IgM units 
(mean ± SD)
MCTD 77 11 66 14.3 3.62 (0–15) 50.4(18–80)
56.3
(45–74)
49.4
(18–80) 61.51 ± 38.72 62.88 ± 33.31
PAPs 65 20 45 30.8 2.98 (0–13) 48.0(25–79)
52.7
(26–67)
49.9
(25–79) 87.85 ± 44.26 97.59 ± 52.16
RA 354 77 277 21.8 1.32 (0–10) 58.0(24–87)
60.3
(28–83)
57.4
(24–87) 88.53 ± 43.68 84.34 ± 45.21
SjS 324 21 303 6.5 1.72 (0–10) 58.3(22–93)
59.4
(26–93)
58.2
(22–86) 68.73 ± 38.91 71.38 ± 37.95
SLE 374 30 344 8.0 2.33 (0–10) 45.8(19–87)
50.0
(23–77)
45.5
(19–87) 68.27 ± 36.54 76.36 ± 44.35
SSc 331 53 278 16.0 4.84 (0–16) 58.2(24–86)
55.4
(34–84)
58.7
(24–86) 76.31 ± 35.90 77.04 ± 39.96
UCTD 118 9 109 7.6 2.10 (0–10) 52.7(19–90)
59.7
(44–80)
52.1
(19–90) 76.11 ± 43.86 83.01 ± 51.82
Control 515 111 404 21.6 0.23 (0–4) 47.6(20–85)
46.3
(25–78)
48.0
(20–85) 73.86 ± 34.25 69.34 ± 34.24
Table 1. Dataset of determinations of IgM anti-PC and anti-MDA.
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Figure 1. (A) IgM Anti-PC in cross sectional cohort, PRECISESADS. There were clear differences between 
different diagnoses. Low levels were observed in SLE, MCTD and SjS. The box plot for anti-PC IgM levels for 
all systemic rheumatic diseases and controls. Box limits indicate the 25th and 75th percentiles, centre lines 
indicate median values, whiskers extend 1.5 times the interquartile range from lower and upper percentiles. 
(B) A different profile was observed in IgM Anti-MDA. Not a clear difference between different diagnoses as 
for IgM anti-PC. A pairwise t-test was done for any two given diseases, orange boxes represent FDR-corrected 
p-values <0.005, light orange boxes represents p(FDR) < 0.05. Violin and box plots at A, B are shown for female-
only data subset. The healthy control group is highlighted in green, the MCTD in red. Inset (C,D): anti-PC 
in MCTD – striking differences as compared to controls. For MCTD case the comparison to healthy controls 
is presented. Box plot shows significant decrease of anti-PC IgM in MCTD (C). No striking differences were 
detected for anti-MDA IgM antibodies (D). T-test p-values shown below boxplots. (E) The heatmap based on 
the fraction of samples for each percentile according to anti-PC and anti-MDA IgM level for MCTD and healthy 
controls. Numbers correspond to the following percentiles: 1 (<=10%), 2 (10–25%), 3 (25–33%), 4 (50–66%), 5 
(66–75%), 6 (75–90%), 7 (>90%). Color scheme for the corresponding fraction (%) of samples is shown below.
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Figure 2. Correlation analysis between cardiovascular score and anti-PC or anti-MDA antibody levels. (a) The 
levels of anti-PC and anti-MDA IgM compared for each disease independently with the cardiovascular score. 
Individual values are shown as dots with the linear trend lines indicated. Spearman’s rank correlations were 
estimated between these values. Negative correlation between IgM level and CV was detected for anti-PC but 
not for anti-MDA for MCTD, SLE, UCTD and RA. No significant correlations were shown for SSc, PAPs and 
SjS subsets. The total all-disease cohort also demonstrated significant negative correlation between anti-PC IgM 
and CV (rho −0.128, 2-sided p-value 1.27e-06), but not for anti-MDA (rho −0.042, 2-sided p-value 0.106). (b) 
Cardiovascular comorbidities and symptoms for all cases. The levels of anti-PC and anti-MDA IgM compared 
for all cases of systemic autoimmune diseases with the cardiovascular score. Individual values are shown as 
dots with the linear trend lines indicated. Spearman’s rank correlations were estimated between these values. 
Negative correlation between IgM level and CV was detected for anti-PC but not for anti-MDA.
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identified as perfect matches to known variable region peptide sequences or derived from de novo sequences with 
sequence homology to the variable regions).
In line with findings from our previous studies using quantitative LC-MS/MS peptide sequencing, we could 
demonstrate that anti-MDA and anti-PC contained significantly lower amounts of lambda chain sequences com-
pared to the corresponding flow through fractions (deprived from the antigen specific IgM). When comparing 
the identified variable peptide sequences (n = 963) from anti-MDA, anti-PC or their corresponding FTs, approx-
imately 50% (n = 471) were not detectable in the anti-MDA and anti-PC IgM.
Among anti-MDA and/or anti-PC IgM peptides, specific CDR peptide sequences (ENDNKFSFDYWG 
QGTLVTVSSASTK and FSFDYWGQGTLVTVSSASTK) in both anti-PC and in anti-MDA were raised signif-
icantly as compared to Ft, Fig. 4A. Furthermore, particularly the anti-PC specific IgM contained HV, KV and 
LV peptide sequences that appears to be specific for this type as demonstrated both by univariate (as shown 
in Fig. 4B and in multivariate (as shown in Fig. 5) data analysis. Particularly the multivariate data which was 
constructed by PCA, (Fig. 5C) and OPLS-DA (Fig. 5A) differentiated the antigen specific IgM to the FT sam-
ples along component 1 (x-axis) and the anti-PC and anti-MDA samples along component 2 (y-axis). From the 
OPLS-DA loading plot the variable region peptide sequences that were abundant in the anti-MDA, anti-PC or 
both anti-MDA/anti-PC were then identified. The most prominent differences between anti-PC and anti-PC-FT 
as well as anti-MDA and anti-MDA-FT, respectively are shown in Supplemental Table 2.
Discussion
We here report that anti-PC IgM is significantly lower among patients with MCTD as compared to controls, 
and also that different systemic autoimmune diseases show different anti-PC and, in less extent, anti-MDA IgM 
level variation. Anti-PC concentration was remarkably different for MCTD, RA, SLE and SjS in comparison with 
healthy controls. Clear differences were found between anti-PC IgM in patients with RA, PAPs and MCTD, with 
higher levels among the former two diagnoses as compared to MCTD. Several diseases were characterized with 
increased fraction of samples with extremely low anti-PC IgM level: SjS, SLE, UCTD. This effect was the most 
pronounced for MCTD, both for anti-PC and anti-MDA.
Figure 3. The proportion of Treg (CD4+CD25+CD127 dim/-) cells in CD4+T cells from the Buffy Coat of healthy 
donors. CD25 and CD127 expression were determined by flow cytometry analysis in CD4+T cells after 6 days 
culture with Treg-polarizing cytokines, with PMA and Ionomycin stimulation. Anti-PC flow, Anti-PC IgM, 
Anti-MDA flow and Anti-MDA IgM were added one day before harvest. The percentage ±SD of three different 
cultures performed. Differences between Treg cells Anti-MDA IgM treatment showed statistically significant. 
(p < 0.05). Differences between Treg cells Anti-MDA IgM treatment showed no statistically significant effects. 
Effects of anti-PC and anti-MDA on Treg polarization.
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MCTD is a relatively rare autoimmune disease and it’s sheer existence as a distinct disorder and diagnostic 
criteria are still debated30,31. Our findings could favour the notion that it indeed is a disease of its own. Our find-
ings are also in line with a recent report where increased risk of cardiovascular disease was present in MCTD32.
The prevalence of low anti-PC IgM in SLE is in line with our previous findings which have been largely con-
firmed by others12–14,16–25.
Anti-PC analysis for MCTD, SSc, UCTD and SjS is presented here for the first time and detected association 
are thus new. Relatively little is known for these antibodies putative role in RA. We didn’t detect lower anti-PC 
level samples in RA, moreover, this level was higher than in controls. Anti-PC IgM can still have some protective 
properties in this pathology but current cross-section design is a limitation. Previously we detected low anti-PC 
levels for non-responders to treatment to biologics in RA18. Other published evidence of a role as protection 
marker of IgM anti-PC comes from studies on vasculitis and even osteoarthritis24.
We also found that anti-PC, but not anti-MDA IgM is negatively associated with broadly defined cardiovascu-
lar symptoms and comorbidities among whole group of patients and, specifically, in MCTD, RA, SLE and UCTD. 
This finding is in line with our previous results on SLE-associated cardiovascular complications16,17.
The important question is if the associations with IgM anti-PC as a protection marker also represent 
underlying mechanisms which could cause or have secondary effects on the disease conditions. The present 
cross-sectional study design does not allow conclusions about cause, and in fact, low levels of anti-PC could have 
different causes. Low anti-PC levels could be caused by the disease and not the other way around, even though 
our previous findings, where low levels predicted disease development, to some extent argues against this possi-
bility. For example, increased oxidation of LDL is a feature of SLE, where OxLDL as determined by PC-exposure 
was increased among patients as compared to controls and also among SLE-patients with CVD as compared to 
Figure 4. Proteomics analysis. Similarities and differences between the polyclonal anti-PC and anti-MDA IgM 
variable regions. Differences in the heavy variable chain CDR2 and CDR3 regions between polyclonal anti-PC 
IgM and non-anti-PC IgM (flowthrough, FT) as well as anti-MDA and anti-MDA-FT samples. The data was 
generated via quantitative proteomics de novo sequencing analysis. Numbers are reported as log(ppm) of the 
relative variable region peptide distributions in respective sample. (A) Peptides from the HV CDR3 region that 
were elevated in the anti-MDA IgM and/or anti-PC samples. (B) Peptides from the HV CDR2 region that were 
elevated in the anti-PC IgM samples.
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those without33. Thus, both atherosclerosis and SLE, could in principle trigger consumption of anti-PC. It is also 
possible that immune complexes could play a role, which contain the antigens studied34. Still, even if consumption 
and immune complex formation contributes, low levels of antibodies still predict disease. We have demonstrated 
that levels of IgM anti-PC are positively associated with anti-PC production by B-cells. We suggest that this argues 
against consumption being a cause of low levels, though it’s contribution cannot be completely ruled out35.
There are several lines of evidence in support of IgM anti-PC being not just a disease marker but also a poten-
tial contributing factor. The risk of CVD in SLE is increased, which is likely to be related to such risk factors as 
being oxidation leading to PC-exposure and being low anti-PC levels33. Anti-PC could be protective by inhibiting 
OxLDL uptake into inert macrophage-derived foam cells36, and also could inhibit cell death caused by a major 
OxLDL component37. Further, anti-PC is anti-inflammatory by inhibiting the effects of inflammatory phospho-
lipids17. We previously reported that IgM anti-PC increase clearance of dead and dying cell26, this notion is in 
line with animal experiments showing increased uptake of apoptotic cells by IgM anti-PC38. Inefficient dead cells 
clearance may contribute to SLE and likely to other systemic autoimmune disorders, at least such as MCTD39. 
Recently we demonstrated yet another mechanism which potentially could be protective both in atherosclero-
sis and CVD, as well as in rheumatic diseases. Hence, we found that IgM anti-PC promotes polarization of T 
Figure 5. Differences in the heavy variable chain regions between the anti-PC, anti-MDA and FT samples as 
determined via multivariate data analysis using the proteomics de novo sequencing quantitative data. (A) Scores 
plot of the OPLS-DA multivariate analysis of the anti-PC samples (group 1), anti-MDA samples (group 2) and 
anti-PC-FT and anti-MDA-FT samples (group 3) using heavy variable, lambda variable and kappa variable 
chain peptides that were identified in both FT and anti-PC or anti-MDA samples or identified in anti-PC or 
anti-MDA only. The generated model (R2 = 0.9, Q2 = 0.7, p = 0.0003) contained two predictive components 
(axis x and axis y). The scores plot shows distinct separation between the FT and antigen specific IgM samples 
along the x-axis and separation between the anti-MDA and anti-PC IgM samples along the y-axis. (B) Loading 
plot showing how the peptides correlate with respective subgroup. From the plot it is evident that the majority 
of peptides correlate with the FT but that particular peptides are specific for anti-PC (nr. 1–8) and anti-MDA 
(nr 17–19). Furthermore, a number of peptides (those negatively correlating with the FT and oriented between 
anti-MDA and anti-PC), are peptides that were elevated in both anti-PC and anti-MDA IgM but low in 
abundance (or missing) in the FT (nr. 9–16). Note that we have previously described nr 11–17 and 19 as anti-
MDA specific15. (C) The corresponding PCA scores plot of the data.
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regulatory cells, both in from atherosclerotic plaques and SLE-patients28. In SLE, Tregs were lower than among 
controls which is in line with previous studies where Tregs were negatively associated with SLE40. In an interesting 
recent study, IgM anti-PC was confirmed to be depressed in SLE and associated with atherosclerosis in this con-
dition. Further, Low IgM anti-PC was associated with high triglyceride and low HDL – a pro-inflammatory lipid 
profile - and also to low Treg levels. This finding is highly compatible with the notion that IgM anti-PC promote 
Treg polarization25.
In our study the levels of Tregs were normalized by IgM anti-PC treatment which was raised to the same levels 
as healthy controls28. Tregs are known to be decreased in MCTD and could be a contributing factor in disease 
pathogenesis and development41. In principle, low anti-PC levels could thus contribute to low Treg-levels. Low 
or dysfunctional Tregs have also been implicated in SjS42 and in SSc. However, even though several publications 
indicate low levels in SSc, this is more controversial and may be related more to dysfunctional Tregs than to their 
reduced levels43.
In contrast to IgM anti-PC, IgM anti-MDA did not differ much between groups26. We still see herein low 
anti-MDA levels in patients, however, strongest findings are for anti-PC. Previously we reported anti-MDA neg-
ative associations with atherosclerosis measurements, which was not performed in the present study. Still, among 
RA and MCTD patients, prevalence of CV-comorbidity was negatively associated with IgM anti-MDA. Of note, 
in the present study, we had broad definitions of CV as compared to the previous study which focused on SLE, 
atherosclerosis and CVD26.
It is possible that IgM anti-PC, and potentially also IgM anti-MDA has a role among some SLE-patients, in 
subgroups, e.g. those with CVD-risk or established CVD and with atherosclerosis. Further studies are needed to 
clarify the role of anti-PC and anti-MDA as risk/protection markers in SLE and also in the other autoimmune 
diseases studied, especially MCTD and SS where we here report significant associations. Anti-MDA has some 
properties in common with IgM anti-PC, such as decreased uptake of OxLDL in macrophages44 which could be 
of importance for atherosclerosis. Thus, this could lead to growth of atherosclerotic plaques with accumulation of 
macrophage-derived foam cells filled with OxLDL, becoming inert and undergoing cell death, through apoptosis 
or necrosis. Our preliminary data indicate that anti-MDA has anti-inflammatory properties, inhibiting effects of 
MDA-epitopes (unpublished). Anti-MDA is also known to increase uptake of human apoptotic cells26.
Interestingly, in contrast to IgM anti-PC, IgM anti-MDA did not have the ability to promote polarization of 
Tregs. There is thus a possibility that this difference between the antibodies could explain the apparently higher 
protective potential of IgM anti-PC in our study.
By use of proteomics analysis, we also demonstrate interesting differences between IgM anti-PC, anti-MDA 
and control IgM. We have previously published quantitative LC-MS/MS peptide sequencing data for anti-PC28 
and anti-MDA variable regions15. Herein we reanalyzed the data to compare and identify potential similarities 
and differences between the two antigens specific IgM peptide profiles with focus on peptides derived from the 
variable region. Both anti-MDA and anti-PC contained significantly lower amounts of lambda chain sequences 
compared to the corresponding flow through fractions (deprived from the antigen specific IgM). We also demon-
strate that the antigen specific IgM are more homogeneous than the control IgM (FTs) and contain elevated levels 
of specific IgM variants. Noteworthy, among the anti-MDA and/or anti-PC IgM peptides, we could identify sig-
nificantly elevated levels (compared to the FT) of specific CDR peptide sequences. These findings are thus in line 
with the somewhat different clinical and functional properties of IgM anti-PC and anti-MDA.
It has been described earlier that MDA-modified LDL is scavenged by monocytes/macrophages in athero-
sclerotic plaques and thus could play a role in atherogenesis45. One dominant epitope in MDA-protein adducts 
is acetaldehyde that forms stable dihydropyridine (4-methyl-1,4-dihydropyridine-3,5-dicarbaldehyde), which in 
turn modifies ubiquitous and essential amino acid lysine to a stable product which is implicated in atherosclerosis 
and other inflammatory conditions46.
PC is exposed on oxidized lipids as in OxLDL which is a major component of atherosclerotic plaques. Together 
with the formation/accumulation of dead cells this results in an ongoing chronic inflammation and thus activated 
immune competent cells12,47. OxLDL is also increased in SLE, and associated with CVD, as determined by PC 
exposure, and also other plasma components exhibit increased PC in this condition33. PC is usually described as a 
danger associated molecular pattern, DAMP, which is the case also with MDA. These compounds, when exposed, 
are recognized as danger and something that should be removed. Interestingly, in contrast to MDA, PC is also 
a pathogen associated molecular pattern, PAMP, being of importance on infectious agents including parasites 
and nematodes among others. This could represent yet another interesting difference between these types of 
antibodies. We have proposed a development of the Old friends/Hygiene hypothesis, where lack of exposure to 
PC-exposing microorganisms and pathogens as nematodes and parasites could lead to lower levels of anti-PC and 
as consequence lower protection against chronic inflammatory conditions. In this process both lipid oxidation 
and PC exposure will play a role. We demonstrated that in Kitava, Papua New Guinea, anti-PC is very high, and 
these diseases are non-existing48,49. We also demonstrated that one pathogen implicated could be Treponema, 
causing Yaws in these areas50.
There are several limitations in this study. One is the cross-sectional design, where we cannot draw conclu-
sions about a potential role in predicting disease manifestations in relation to the antibodies studied. Also other 
IgM antibodies including total IgM could be of interest to study, but in this study we focused on those which 
appear most promising in relation to disease and outcome. It could also be of interest in further studies to analyse 
if different carriers for these epitope could make any difference. The experimental studies of antibodies in relation 
to Tregs are not the main topic of this studies, and larger studies of T cell populations and T reg polarization are 
needed to confirm this relatively small sample, even though our results were significant.
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conclusions
Our data indicates that anti-PC but probably not anti-MDA IgM may play a role as a marker in systemic auto-
immune diseases such as MCTD, SjS and SLE, and where the negative associations were strongest for MCTD. 
Our findings also confirm and extend previous observations of negative associations between these IgMs and 
CVD in autoimmune patients. Our results are compatible also with anti-PC contributing to the diseases per se, 
since several mechanisms which potentially could be protective have been identified, incuding promotion of Treg 
polarization. It remains to be seen, however, if raising anti-PC with active or passive immunization is beneficial.
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